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Abstract: In this study, cell death regulation and induction in AML cell line from a relapsed MLL-
rearranged cell model (MOLM-13) was investigated with doxorubin (Dox) and betulinic acid (BetA),
singly and in combination. CyQUANT Direct® and Annexin V/propidium iodide double staining
were used to measure the cytotoxic and cell death induction effects of the compounds, respectively.
Reactive oxygen species (ROS) generation was measured using 2′,7′-dichlorofluorescin diacetate
staining. Expressions of proteins and genes were examined by Western blot and reverse transcription
polymerase chain reaction analysis, respectively. BetA (20 µM) and Dox (1 µM) indicated a synergistic
growth inhibitory effect on MOLM-13 cells. The combined drug caused more cells to reside in
irreversible late apoptotic stage compared to the single treatments (p < 0.05). Elevation in ROS
may be the synergistic mechanism involved in MOLM-13 cell death since ROS can directly disrupt
mitochondrial activity. In contrast, in leukaemic U-937 cells, the combination treatments attenuated
Dox-induced cell death. Dox and the drug combination selectively reduced (p < 0.05) a recently
reported anti-apoptotic Bcl-2 protein isoform p15-20-Bcl-2 in MOLM-13 by our group, without
affecting the usually reported p26-Bcl-2-α. Further studies using known inhibitors of apoptosis are
required to confirm the potential of Dox-BetA combination to modulate these pathways.
Keywords: acute myeloid leukaemia; doxorubicin; betulinic acid; apoptosis; drug combination;
B-cell lymphoma 2 family of proteins; reactive oxygen species
1. Introduction
Betulinic acid (3β,hydroxyl-lup-20(29)-en-28-oic acid, BetA), pentacyclic triterpenoid,
has been reported to be effective against relapsed acute myeloid leukaemia (AML) cells
when tested alongside standard AML chemotherapeutics such as doxorubicin (Dox) and
cytarabine (tested at clinically relevant concentrations) [1]. Furthermore, it has been
reported that BetA exerts some selectivity towards cancer cells whilst being less toxic
towards non-cancerous cells. This effect has been described in both blood cells and cells
of epithelial origin, such as human primary melanocytic cells [2], normal colon cells [3],
peripheral blood mononuclear cells [4], and normal peripheral blood lymphoblasts [5].
Therefore, the compound could be a good candidate for drug combination studies with
standard chemotherapy treatments as it has been suggested to enhance drug-induced cell
death or sensitize the cancer cells to a drug [6]. Most studies have reported that BetA-
induced cell death in cancer cells is through apoptotic death, specifically by affecting the
intrinsic (mitochondrial) pathway [1,7–9]. However, due to inconsistent reports between
different cell types on the role of Bcl-2 family regulation by BetA [10–13], further studies
are warranted to examine BetA’s mechanism of multiple drug interaction and synergism.
Apoptosis is a programmed cell death pathway that is usually the primary target
of most chemotherapy drugs [14]. For instance, Dox, an established AML drug [15],
works as a topoisomerase II inhibitor [16,17] and has been reported to induce apoptotic
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cell death in various cancers [18–22]. This cell death signalling is regulated via extrinsic
or intrinsic apoptotic pathways, which leads to proteolytic events that activate enzyme
caspases to execute cell death [23,24]. Apoptosis through the extrinsic pathway is triggered
by death receptors present on the cell surface while the intrinsic pathway is activated by
mitochondrial perturbation [25,26]. Mitochondrial membrane permeability is regulated by
reactive oxygen species (ROS), as well as by B-cell lymphoma 2 (Bcl-2) family of proteins,
which are either pro-apoptotic (Bax, Bak, Bad) or anti-apoptotic (Bcl-2, Bcl-XL, Mcl-1).
These proteins contain BH3 domain that can form a binding groove, which allows them to
interact and facilitate or antagonise each function [27]. Some cancers, including AML cells
abnormally regulate the Bcl-2 family of proteins [28–31], which could contribute to their
refractory nature in relapsed incidents.
Some cancer cells can develop chemoresistance by stimulating autophagy [32]. This
cellular process is tightly linked to apoptosis through Beclin 1:Bcl-2 complex regulation,
where Bcl-2 can suppress the autophagic function of Beclin 1 [33]. This is because Beclin
1 also contains a BH3 domain and is essential in initiating the phagophore formation
of the autophagosome [33]. Autophagy is a dynamic cell process that initiates cell sur-
vival/protection, as well as promoting cell death [25,32], thus modulating this pathway
could be useful in fighting cancerous cells [33,34]. Cellular stress triggers this signalling
pathway, which leads to formation of isolation membranes and vesicles that recycle aged
cellular content [26,34,35].
We have recently published findings of a possible Bcl-2 variant, p15-20-Bcl-2 in AML
MOLM-13 cells, which was selectively targeted by Dox [22]. This currently reported study
aimed to determine if combining BetA and Dox could enhance the cytotoxicity of Dox to
MOLM-13 cells.
2. Materials and Methods
2.1. Cell Culture
An authenticated leukaemic MOLM-13 cell line (immortalized AML cell line derived
from a relapsed patient with MLL-rearrangement) was purchased from the European Col-
lection of Cell Cultures, Public Health England and maintained in Roswell Park Memorial
Institute (RPMI) 1640 (Sigma-Aldrich; Merck KGaA, UK) medium. The AML U-937 (ATCC
CRL-1593.2) cell lines were purchased from American Type Culture Collection. U-937 cells
were grown and maintained in Iscove’s Modified Dulbecco’s medium (Sigma-Aldrich;
Merck KGaA, UK). This study compares two AML cell lines of relapsed (MOLM-13) and
non-relapsed (U-937) origin with different mutations.
Mycoplasma-free cells (tested by polymerase chain reaction) were used throughout
the experiments. The culture mediums were further supplemented with 1% L-glutamine,
1% penicillin-streptomycin antibiotic and 10% foetal bovine serum (Sigma-Aldrich; Merck
KGaA, UK) and the cells were grown in a humidified incubator at 37 ◦C in 5% CO2
environment. The medium was replenished every 48–72 h through cell pelleting by
centrifugation. Experiments were done on cells with a viability of at least 97% in logarithmic
growth, which was tested by Trypan blue (HyClone®, South Logan, UT, USA) dye assay
to determine cell density. Cells were manually counted at 1:1 ratio with the dye using a
haemocytometer under light microscopy.
2.2. Drugs and Treatment Concentrations
BetA 20 µM was selected as a suitable concentration for combination studies since
BetA 10 µg/mL (22 µM) has been reported to be non-toxic in human cells in in vitro
studies [1,36]. This concentration is relative to 100 mg/kg administration and found to be
non-toxic in in vivo studies [37]. The Dox concentrations chosen were within 0.1–1 µM, a
range that is equivalent to clinical concentrations [38]. Dox 0.5 µM and 1 µM were selected
concentrations for combination with BetA 20 µM.
To determine the non-cytotoxic concentration range of DMSO suitable for solubilising
the test drugs, the effect of DMSO (0.05% to 1%) on various cell lines was investigated
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in preliminary experiments (data not shown). Cell viability was assessed by CyQUANT
Direct®. Up to 0.07%, DMSO was found to be non-toxic; 0.05% DMSO was selected
as the final concentration for the dissolution of test compounds, maintaining the same
level of DMSO concentration in all the treatments, including those for the negative and
positive controls.
Stock solutions (20× the final conc.) of betulinic acid (BetA; Sigma-Aldrich; Merck
KGaA, Gillingham, UK) and doxorubicin (Dox; Sigma-Aldrich; Merck KGaA, UK) were
prepared in 1% DMSO (in medium or PBS) and the cell treatments were conducted in
1:20 dilution, with a final concentration of 0.05% DMSO in all treatments. The final
concentrations of the drugs in cell treatments were as follows: BetA (20 µM), Dox (0.5 µM,
1 µM) or a combination of both BetA and Dox was added.
The effect of the treatments on the cells was investigated by using two different ap-
proaches, by cell viability with CyQUANT Direct® and by differentiation of the population
of live and dead cells through Annexin V and PI staining. The cell health in CyQUANT
Direct® assessment was only by the level of nucleic acid of viable cells in cell treatments
relative to the control. Cell death population by Annexin V/PI was displayed in the ratio
of live cells and different cell death (early apoptosis, late apoptosis, and necrotic cells).
2.3. Determination of Cell Viability and Cytotoxicity Using CyQUANT Direct® Assay
MOLM-13 and U-937 cells were seeded at 5 × 105 cells/mL in 96-well plates, treated
(with single or combined treatments of BetA and Dox; Section 2.2), and incubated for
24 h. Cells treated with the DMSO vehicle (final conc. 0.05%) were used as negative con-
trol. After the treatment period, CyQUANT Direct® (Invitrogen, Thermo Fisher Scientific;
Loughborough, UK) dye was overlaid in each well (in a 96-well plate) and incubated
for a further 45 min (in a humidified incubator at 37 ◦C) to determine the viability of
the cells. CyQUANT® detection dye was prepared by mixing nucleic acid stain (0.4%),
background suppressor I (2%), and culture media (97.6%). CyQUANT dye stains nu-
cleic acids (RNA and DNA) in dividing cells and is used as an indicator of cell number
since DNA/RNA content is highly and tightly regulated in live cells [39,40]. To com-
pensate for drug (particularly for Dox) Dox auto-fluorescence, individual blank controls
(drug + diluent) were used for each sample to subtract background fluorescence. The
fluorescence of the samples was measured using a microplate reader FLUOstar Omega
(BMG Labtech) at 1000 gain at 485 nm excitation and 520 nm emission wavelength.
2.4. Cell Death Population Assays Using 488 Annexin V and PI: Flow Cytometry
MOLM-13 and U-937 cells (1 × 106 cells/mL) were treated with BetA, Dox, or BetA
combined with Dox (see Section 2.2) for 24 and 48 h in 5% CO2 and at 37 ◦C. Cells treated
with 0.05% DMSO vehicle were used as positive and negative controls, respectively. As
previously described [22], flow cytometry analysis was used to differentiate viable and dead
(early/late apoptosis and necrosis) cells using Alexa Fluor® 488 Annexin V (Thermo Fisher
Scientific) method. The cell events of live and dead populations were characterised by
quadrant separation and presented as mean percentage ratio of three biological replicates.
The difference in the cell population (live and dead) was compared between the control
and treatments.
2.5. Reactive Oxygen Species (ROS) Formation
DCFDA cellular ROS detection assay (Abcam, Cambridge, UK) was used to measure
ROS activity in cells using the fluorogenic dye 2′,7′-dichlorofluorescin diacetate (DCFDA).
The oxidation product, 2′,7′–dichlorofluorescein is highly fluorescent and was measured
to estimate ROS levels in the cells. Harvested MOLM-13 cell lines were first washed in
cold PBS followed by 1× buffer wash. The cells were then stained by suspending them
in DCFDA solution (20 µM) at a concentration of 1 × 106 cells/mL and incubated at
37 ◦C for 30 min in the dark. After incubation, the cells were washed in 1× buffer and
re-suspended at 1 × 106 cells/mL in 1× supplement buffer (1× buffer containing 10% FBS)
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and seeded at 95 µL/well in a 96-well microplate. Cells were then treated by BetA, Dox, or
BetA combined with Dox (see Section 2.2) and incubated at 37 ◦C in 5% CO2. Tert-butyl
hydrogen peroxide (TBHP) (final conc. 50 µM) and Dox (final conc. 5 µM) were used as the
positive control drugs, and the vehicle (DMSO final conc. 0.05%) as the negative control. In
addition, drug-treated but unstained cells and untreated cells were also used as controls.
The fluorescence of 2′,7′–dichlorofluorescein was measured at 30 min intervals up to 3.5 h
using a FLUOstar Omega microplate reader (BMG Labtech) at 1000 gain, 485 nm excitation
and 520 nm emission wavelengths.
2.6. Investigation of Proteins Involved in Cell Death: Western Blot Analysis
2.6.1. Cell Treatment
The cells were treated with BetA, Dox, DMSO (final conc. 0.05%; vehicle control) and
two combinations of BetA (final conc. 20 µM) with Dox (final conc. 0.5 or 1 µM). The treat-
ments were incubated for 48 h at 37 ◦C in humidified atmosphere of 5% CO2. Whole cell
lysis, protein SDS-PAGE separation, membrane transfer, immunoblotting and visualisation
were performed following methods that were previously described in detail [22].
2.6.2. Antibodies
The primary antibodies used were as follows: anti-Bcl-2 (1:1000 in 5% milk; Abcam
cat. No. ab32124), anti-Bax (1:1000 in 5% milk; Abcam cat. No. ab32503), and anti-Beclin
1 (1:2000 in 5% BSA; Abcam cat. No. ab207612). All were probed with a secondary
antibody Goat Anti-Rabbit IgG (H + L) horseradish peroxidase (1:3000 in 5% BSA or 5%
milk; BIO-RAD cat. No. 170-6515). Primary antibody for β-actin (1:5000 in 5% BSA;
Abcam cat. No. ab8226) was used as a housekeeping protein control, which was probed by
another secondary antibody, Goat Anti-Mouse IgG (H + L) horseradish peroxidase-labelled
secondary antibody (1:3000 in 5% BSA or 5% milk; BIO-RAD cat. No. 170-6516).
2.7. Investigating Gene Regulation via RT-PCR
2.7.1. Cell Treatment and RNA Isolation
MOLM-13 and U-937 cells at 1 × 106 cells/mL density were treated with BetA, Dox,
or combination treatment of BetA (final conc. 20 µM, 25 µL) with Dox (final conc. 1 µM,
25 µL) for 48 h, with DMSO (final con. 0.05%) as a vehicle control. Prior to RNA isolation,
the cells were pelleted via centrifugation, snap frozen in liquid nitrogen and stored at −80
◦C. The RNA samples were obtained using a silica membrane binding method utilised
within the Isolate II RNA mini assay (Bioline, London, UK). The RNA concentration
and purity were checked using a Nanodrop (NanoDrop 2000/2000c, Thermo Scientific,
Loughborough, UK).
2.7.2. Reverse Transcription–Polymerase Chain Reaction (RT-PCR)
A standard amount of RNA at 200 ng, for all samples, was converted to cDNA by
reverse transcription and amplified by PCR utilising a one-step RT-PCR method; the My-
TaqTM One-Step RT-PCR Kit (Bioline, UK) in a thermal cycler (Techne® Prime, Bibby
Scientific, Stone, UK). Isolated RNA was prepared in a final volume of 25 µL in a mixture
containing 12.5 µL 2×MyTaq One-Step Mix, 0.25 µL reverse transcriptase, 0.5 µL RiboSafe
RNase Inhibitor (10 U/µM), and 1 µL of respective forward and reverse primers. Specific
volume of Diethyl Pyrocarbonate (DEPC) H2O was used to dilute and standardise the
RNA template to 200 ng. Samples with the same mixture but without the RNA template
was used as non-template control. The RT-PCR conditions on the thermocycler were as
follows: reverse-transcription (1 cycle, 45 ◦C, 20 min), polymerase activation (1 cycle, 95 ◦C,
1 min), denaturation (30 cycles, 95 ◦C, 10 s), annealing (30 cycles, 60 ◦C, 10 s), and extension
(30 cycles, 72 ◦C, 30 s). Specific primers for pro-apoptotic BAK and BAX, anti-apoptotic
BCL-2 and BCL-XL, autophagy marker ATG5 and BECLIN 1 (Table 1; all from Invit-
rogen, Thermo Fisher Scientific) and for the housekeeping gene GAPDH (Invitrogen,
Thermo Fisher Scientific) (Fwd: ACCACAGTCCATGCCATCAC; Rev: TCCACCACCCT-
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GTTGCTGTA) were used for gene targeting. An intercalating DNA binding stain, SafeView
(5 µL/100 mL agarose), was added to the 1.5% agarose gel. PCR products were loaded
into the gel and the electrophoresis was carried out at a constant 90 V for 30 min. The gel
image was visualised under UV illumination using an UVP GelDoc-It® imaging system
2UV transilluminator. Densitometry was carried out using ImageJ software (Madison,
WI, USA).
Table 1. Primer design for apoptotic Bcl-2 family and autophagy genes.























Fwd—forward primer, Rev—reverse primer.
2.8. Data and Statistical Analysis
The data was analysed using Minitab 18® software (State College, PA, USA) for
statistical comparison. The data was expressed as a mean percentage ± SE relative to
the vehicle control from a sample size of at least three replicates. The data was analysed
using (independent) two sample t-test (comparison of two means) or one-way ANOVA
(comparison of multiple means) after performing Anderson–Darling normality test and
equal variance test, all with 95% coefficient interval. One-way ANOVA was followed by
Tukey (honest significant difference) post-hoc testing. A p-value ≤ 0.05 was accepted as
statistically significant.
Combination index (CI; value which determines multiple drug interaction) was calcu-
lated by the Chou–Thalaya method using CompuSyn software (ComboSyn, Inc.; Paramus,
NJ, USA). Data for cell viability and cell inhibition measured by CyQUANT Direct was
used to generate a dose-effect curve and a median-effect plot. Data were obtained for
combination of non-constant ratio design. CI was calculated by the following formula (CI








where D is the concentration of single drugs and Dx, a dose of D alone, which gives x
inhibition. Drug synergism was accepted with CI < 1, additive effect with CI = 1, and
antagonism with CI > 1.
Data acquired by flow cytometry (cell death Annexin V/PI) were further analysed
by Flowing Software program (free-downloadable software developed by Perttu Terho,
version 2.5.1; Turku, Finland). Distinctive gating was applied on cell population events
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to compensate for auto-fluorescence of Dox and back-gating was used to define cells that
were double-stained with Annexin V and PI when analysing the cell population data.
3. Results
3.1. Combination of Betulinic Acid and Doxorubicin Synergistically Reduced Cell Viability in
MOLM-13 AML Cell Line, but Did Not Significantly Affect the Viability of U-937 Cells
Experiments were conducted to determine if BetA could enhance the cytotoxic effect
of Dox death in a relapsed AML cell model (MOLM-13) and compare this effect to another
AML cell (U-937). Sole treatments of Dox 0.5 µM and 1 µM significantly reduced the cell
viability of MOLM-13 (p < 0.01 and p < 0.001, respectively (Figure 1a)), compared to vehicle
control (DMSO 0.05%). A non-statistically significant effect was shown in U-937 monocytes
treated by Dox (0.5 and 1 µM) at 24 h, despite the suppression of U-937 cell growth by 24%
when treated with Dox (1 µM). BetA (20 µM) showed selective cytotoxicity by inhibiting
MOLM-13 cell growth at 24 h by 26% (p < 0.05) without a growth inhibitory effect on U-937
(Figure 1a,b).
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based on Chou–Talaya method by combination index (CI) using CompuSyn (non-constant ratio design). Additive effect
(CI = 1), synergism (CI < 1), antagonism (CI > 1).
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Co-treatment of BetA and Dox at 24 h showed selective cytotoxicity towards the
MOLM-13 cell line (Figure 1a). BetA 20 µM combined with Dox 0.5 µM or Dox 1 µM
showed highly significant cell growth inhibition in MOLM-13 by 30% (p < 0.01) and 60%
(p < 0.001), respectively, at 24 h. No statistical effect on cell growth was observed on U-937
monocytes by the same combination treatments, despite an increase in cell numbers by 20%
at BetA 20 µM and Dox 0.5 µM combination (Figure 1b). Therefore, combination treatments
were cytotoxic to the leukaemic relapsed cell model but did not significantly affect the cell
viability of monocytic U-937 cells.
Comparison of statistical mean difference between single drugs and combination
treatments in MOLM-13 gave contradicting outcomes when using parametric statistical
tests, which compares variances (ANOVA; post-hoc Tukey and two sample t-test). The
effect of the combined drug was not statistically significant when compared to the sole
treatment with Dox 1 µM based on ANOVA (p > 0.05), while significant (p < 0.05) with
two sample t-test analysis (Figure 1(aII)). However, the Chou–Talaya method using com-
bination index (CI) has been reported to be a more reliable way to interpret results for
combinational studies over analysis of variances [41,42]. Based on the CI value, the in-
hibition effect of BetA combined with Dox 1 µM was indicative synergistic (CI < 1) in
suppressing the viability of MOLM-13 at 24 h incubation. However, BetA combined with
0.5 µM Dox was indicative antagonistic (CI > 1) in their inhibitory effect. Although not
showing the conventional antagonistic trend (increase in cell viability), the terminology
‘antagonist effect’ was used based on the combination index (CI) value generated by Chou–
Thalaya method.
3.2. Combination Treatments Induced Apoptotic Death in MOLM-13 AML Cell Line, but Rescued
U-937 Cells from Doxorubicin-Induced Cell Death
Annexin V and Propidium Iodide (PI) double staining was used to examine the effect
of drug-induced cell death and to determine the proportion of cells in different apoptotic
stages (Figure 2a). Cell death was observed in single Dox treatments, as well as Dox and
BetA co-treatments in MOLM-13 cell line at 24 and 48 h incubation with very high statistical
differences (p < 0.001), compared to vehicle control. However, BetA (20 µM) alone induced
similar apoptotic death profile compared to DMSO control with p > 0.05 at both time points
(Figure 2b). Co-treatments of the combined drugs with MOLM-13 showed a slight shift in
the ratio of distinct cell death population when compared to single Dox. At 24 h, about
10% (p < 0.05) more cells resided in reversible early apoptotic stage (+ve Annexin V, −ve
PI) and 8% (p < 0.01) less cells in irreversible late apoptosis (+ve Annexin V, +ve PI) with
Dox 0.5 µM, when compared to the equivalent Dox co-treatment with BetA. In addition,
combination treatment of Dox 1 µM and BetA had significantly more (11%, p < 0.05) cells
in late apoptosis compared to Dox 1 µM alone at 24 h. At 48 h, the lower combination
(Dox 0.5 µM and BetA 20 µM) had significantly more cells (17%, p < 0.05) present in late
apoptosis and less viable cells (23%) compared to 0.5 µM Dox (Figure 2b), however, it was
not statistically significant. At 48 h, Dox 1 µM killed most of the MOLM-13 cells (92%),
whereas Dox 1 µM and BetA combination induced 97% cell death. This difference was
non-statistically significant.
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In U-937 cells at 24 h incubation, Dox treatments showed no statistical significance in
cell population shift compared to the vehicle control cells, despite Dox 0.5 µM appearing
to have more cells in necrosis (12%) and Dox 1 µM more cells in early apoptosis (24%).
BetA (20 µM) alone showed no significant change in cell death induction or cell viability
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suppression when compared to the control, nor enhanced the cell killing ability of Dox
treatments (Figure 2c). Combination treatments on average have more viable cells present
compared to their single Dox counterparts (without significance). At 48 h incubation, cell
death induced in U-937 cells by both concentrations of Dox (0.5 and 1 µM) was more
pronounced compared to the control treatment (viable cell reduction; p < 0.001), with the
majority of cells residing in late apoptosis (p < 0.001; 42% in Dox 0.5 µM and 23% in Dox
1 µM). Although, sole treatments of BetA in U-937 cells at 48 h showed statistically less
viable cells (9%; p < 0.05) than the control, none of the cell death populations were sig-
nificantly different. Moreover, BetA with Dox co-treatment attenuated Dox-induced cell
death in U-937 cells by roughly 25% and 13% compared to equivalent single Dox 0.5 µM
(p < 0.001) and 1 µM (p < 0.01), respectively (Figure 2c).
Interestingly, the effect of Dox in terms of apoptotic population over 48 h did not
show much variation. Although the incubation period did not have much impact on
the concentrations of Dox tested, the overall ratio of cell population after Dox exposure
remained steady, which was seen in both cell lines.
3.3. Betulinic Acid and Doxorubicin Combination Enhanced the Formation of Reactive Oxygen
Species in MOLM-13 Cell Lines
Reactive oxygen species (ROS) are associated with the intrinsic (mitochondrial) apop-
totic cell death pathway. In this study, MOLM-13 cells individually treated with the
positive control drugs, Dox (5 µM) or TBHP (50 µM), significantly (p < 0.001) stimulated
ROS generation. Although single treatments of low dose Dox (0.5 or 1 µM) induced cell
apoptosis in MOLM-13, they failed to exhibit an increase in ROS levels after treatment
of MOLM-13 cells with the drugs for up to 3.5 h (Figure 3). Single BetA (20 µM) treat-
ment did not significantly alter the levels of ROS when compared to the vehicle control.
However, the combined treatments stimulated ROS production within 1.5 h after cell
treatment (p < 0.001 when compared to vehicle control). In addition, the combination
treatments significantly enhanced ROS generation when compared to single Dox treat-
ments. BetA augmented Dox 0.5 µM and 1 µM ROS levels to 1.3–1.4-fold within 0.5–3 h
(p < 0.05) and 1.4-fold at 0.5 h (p < 0.001), respectively.
3.4. Doxorubicin, Alone and in Combination with Betulinic Acid, Inhibits a Novel Isoform of Bcl-2
in AML MOLM-13 Cells without a Potent Effect on the Main Bcl-2 Isoform
Sole BetA 20 µM did not significantly alter the expression of Bcl-2 or Bax protein.
Additionally, the effect of Dox on apoptosis-regulating proteins and the isoforms was not
enhanced when combined with BetA. Therefore, BetA did not enhance but also did not
interfere with the effect of Dox in regulating the pro- and anti-apoptotic proteins Bax and
Bcl-2 in MOLM-13 (Figure 4).
The expression level of Bax pro-apoptotic protein was increased by single Dox and
combination treatments, but this protein elevation was not statistically different between
the treatments and vehicle control, except for 1 µM Dox treatment that increased Bax level
by 2.1-fold (p < 0.05) (Figure 4c). The active Bax protein is antagonised when bound to
Bcl-2 protein in a complex. Dox and combination treatments reduced the level of Bcl-2
anti-apoptotic protein in MOLM-13. However, the decrease was statistically significant
only for the smaller Bcl-2 of 15–20 kDa (p15-20-Bcl-2) and not in the bigger 26 kDa Bcl-2
isoform (p26-Bcl-2-α), when compared to vehicle control. Therefore, the treatments potently
affected the novel truncated p15-20-Bcl-2 reported by Vu et al. (2020) [22]. When the Bcl-2
isoforms were combined, statistical reduction (p < 0.05, compared to vehicle control) was
shown only with the combination treatment of Dox 1 µM and BetA 20 µM (Figure 4b).
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Figure 3. Reactive oxygen species stimulation in MOLM-13 after treatment with doxorubicin, betulinic acid and their
combination. The cells ere t i it µ CF A following 0.5, 1.5, 3 or 3.5 h co-treatment with BetA (20 µM),
Dox (0.5 or 1 µM) or a combination of the drugs. TBHP (50 µM) was used as a positive control. ROS stimulation was
measured as the fluorescence of the treatments using FLUOstar Omeg (BMG Labtech) at 485/520 nm, excitation and
emission, respectively. Data are expressed as the mean ±SE of four replicate (n = 4) measurements in one representative
experiment. The data were analysed by one-way ANOVA using Tukey post-hoc analysis. Dox and the combined treatments
were compared by two sample t-test.
To assess the susceptibility of the AML cells undergoing apoptosis, Bax/Bcl-2 ratio
was evaluated (Figure 4(eI)). All treatments, except for sole BetA, increased the ratio in both
Bcl-2 isoforms, with the Bax/Bcl-2 ratio of p15-20-Bcl-2 being much greater. Moreover, the
ratio difference when comparing single Dox and the combination with BetA was similar
regardless of the Bcl-2 isoform. Combination of Dox 0.5 µM and BetA 20 µM slightly
enhanced the ratio more than single Dox 0.5 µM treatment: an increase by 1.2–1.3-fold. On
the contrary, the ratio increase of Dox 1 µM and BetA 20 µM combination was marginally
lower when compared to Dox 1 µM treatment, a reduction by 1.2-fold.
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Figure 4. The effects of BetA, Dox and combination on apoptotic Bcl-2 family and autophagy Beclin 1 protein expressions
on the MOLM-13 cell line. The protein expressions of BH3-containing proteins, autophagic Beclin 1 (52 kDa), anti-apoptotic
Bcl-2 (26 and 15–20 kDa) and pro-apoptotic Bax (21 kDa) were estimated by Western blot (a). Experimental samples were
run on the same gel and shown protein expressions are on the same blot for each protein antibody. Bcl-2 (b), Bax (c) and
Beclin 1 (d), protein levels were determined by normalising quantified protein intensity relative to vehicle control (DMSO
0.05%, r pre ented as 1.00-fold) ratio b tween ormalised data and β-actin (housekeeping protein). Data were expr ss
mean + SE (n = 3) and analysed by one-way A OVA; Tukey post-hoc tes . Statistical difference was ccepted as following:
p > 0.05 no significant difference (NSD), * p ≤ 0.05 significant, ** p ≤ 0.01 highly significant, *** p ≤ 0.001 very highly
significant. Relative change in the ratio (e) of Bax/Bcl-2 (I) and Beclin1/Bcl-2 (II) were expressed as the fraction of the mean
protein levels.
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3.5. Autophagy Marker Beclin 1 Was Reduced by Doxorubicin and Betulinic Acid Co-Treatment in
AML Cell Line
Expression of Beclin 1 protein, an autophagy marker, was significantly decreased in
MOLM-13 cells when treated with Dox alone (0.5 µM, p < 0.001 and 1 µM, p < 0.001) and
Dox combined with BetA 20 µM (Dox 0.5 µM, p < 0.01 and 1 µM, p < 0.001) when compared
to the expression of vehicle control (Figure 4d). The decrease of Beclin 1 protein was in a
dose-dependent manner. Single BetA 20 µM slightly reduced the protein expression but
with no statistical significance when compared to the control. In addition, there was no
apparent effect of BetA on Dox activity in regulating the Beclin 1 expression.
To evaluate autophagy–apoptosis regulatory pathway and explore its association with
cell death, Beclin 1/Bcl-2 ratio was calculated. The ratio was dose-dependently reduced
by Dox and combination treatments with the established p26-Bcl-2-α, but no marked
change was shown with BetA treatment. Moreover, there was a pronounced reduction
in Beclin 1/p26-Bcl-2-α by Dox and combination treatment, which was in contrast to the
Beclin1/p15-20-Bcl-2 ratio where there was less reduction (Figure 4(eII)). The effect of the
drugs (singly and combined) on the Beclin 1/Bcl-2 ratio across p26-Bcl-2-α, p15-20-Bcl-2,
and combined isoforms (Bcl-2, p26 + p15-20) was similar. Dox 0.5 µM and BetA 20 µM
combination marginally increased Beclin 1/Bcl-2 ratio by 1.5-fold compared to single Dox
0.5 µM. In contrast, combination of Dox 1 µM and BetA 20 µM slightly reduced the ratio
by 1.4-fold compared to single Dox 1 µM treatment (Figure 4(eII)).
3.6. Apoptotic and Autophagy Signalling Protein Levels Were Not Altered by the Treatments in
U-937 Cells
In U-937 monocyte cells, none of the treatments altered significantly the expression
levels of anti-apoptotic Bcl-2 after 48 h treatment when compared to the vehicle control.
Furthermore, only one isoform of Bcl-2 (p26-Bcl-2-α) was expressed in U-937 cells and
there was no detection of any other isoforms such as p15-20-Bcl-2 that was reported in
MOM-13 cells (Figure 5a). BetA-treated U-937 cells showed on average 1.96-fold increase
in Bcl-2 (26 kDa) expression, but without significance (Figure 5b).
Beclin 1 expression level was not significantly changed by any tested treatments in
U-937 cells when compared to vehicle-treated cells. Although, U-937 cells treated by single
Dox 1 µM marginally declined Beclin 1 protein level (0.7-fold; p > 0.05 compared to vehicle
control), which was significantly (p < 0.01) lower compared to BetA 20 µM treatment
that slightly increased Beclin 1 expression (1.4-fold; p > 0.05 compared to vehicle control)
(Figure 5c).
3.7. Combination Treatment Altered mRNA Expression of Bcl-2 Family Members and Autophagy
towards Cell Death in MOLM-13 Cells, but Survival in U-937 Cells
Alteration in gene level could potentially be associated with the protein expression
change as transcription and translation is tightly linked. Therefore, the gene transcript
(mRNA) was quantified to further examine the mechanism of action and the pathways
involved in cell death induction by the drugs.
Dox and BetA alone marginally, but not significantly, increased the mRNA expression
of pro-apoptotic BAK and BAX genes in MOLM-13 cells compared to vehicle control.
Combination treatments further increased the mRNA of pro-apoptotic proteins when
compared to the control, but only the combination with higher Dox concentration (BetA
20 µM + Dox 1 µM) significantly upregulated both BAK (2.7-fold increase, p < 0.05) and
BAX (6.2-fold increase, p < 0.01). However, the effect was not significantly different when
compared to the equivalent single Dox treatment (Figure 6a).
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Figure 5. Apoptosis and autophagy regulating proteins expression in U-937 monocytes treated by single and combination
drug. Leukaemic cell line U-937 cells were treated by single Dox or combination of BetA and Dox for 48 h. The protein
expressions of autophagy marker Beclin 1 (52 kDa) and anti-apoptotic Bcl-2 (26 kDa) were estimated by Western blot (a).
Experimental samples were run on the same gel and shown protein expressions are on the same blot for each protein
antibody. Bcl-2 (b) and Beclin 1 (c) protein levels were determined by normalising quantified protein intensity relative
to vehicle control (DMSO 0.05%, represented as 1.00-fold) and ratio between normalised data and β-actin (housekeeping
protein). Data were expressed as mean + SE (n = 3) and analysed by one-way ANOVA; Tukey post-hoc test. Statistical
difference was accepted as following: p > 0.05 no significant difference (NSD), ** p ≤ 0.01 highly significant.
Anti-apoptotic BCL-XL mRNA expression was not statistically changed by any of the
tested drugs in MOLM-13 cells, there was no significant difference between treatments
and the vehicle control. Conversely, the anti-apoptotic mRNA BCL-2 expression was
downregulated by the drug treatments. Single Dox treatments dose-dependently reduced
(p < 0.05) BCL-2 expression by more than half in MOLM-13 cells, while BetA alone also
showed a decline (on average by 0.62-fold relative to vehicle control) but with no statistical
significance. Although both combination drug treatments with MOLM-13 cells reduced
(on average) the BCL-2 level, it was significant (p < 0.05) only with BetA 20 µM and Dox
0.5 µM combination. In addition, there was no difference in the mRNA expression between
single drugs and combination treatments (Figure 6b).
The band expression of autophagy genes ATG5 and BECLIN 1 (ATG6) was clearly
detectable in MOLM-13 cells treated by the vehicle control and single BetA treatment. BetA
20 µM alone did not change the regulation of ATG5 and BECLIN 1 genes in MOLM-13
cells, from vehicle control expression. Conversely, ATG5 and BECLIN 1 mRNA expression
in MOLM-13 cells were markedly downregulated to almost undetectable levels by single
Dox treatments and combination treatments compared to vehicle control levels (Figure 6c).
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In U-937 monocytic cells, no significant change in the expression of pro-apoptotic BAK
mRNA was observed between the treatments and the vehicle control. The pro-apoptotic
BAX was significantly (p < 0.001) upregulated in U-937 by single Dox treatments, but single
BetA 20 µM did not change the expression when compared to vehicle control (Figure 7a).
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was accepted as following: p > 0.05 no significant difference (NSD), * p ≤ 0.05 significant, ** p ≤ 0.01 highly significant,
*** p ≤ 0.001 very highly significant.
Interestingly, the effect of Dox treatments (0.5 and 1 µM) on BAX upregulation was
reduced to the expression level of vehicle control when combined with BetA 20 µM in
U-937 cell co-treatments. The difference in BAX mRNA between single Dox and their
relevant BetA combination was very highly significant (p < 0.001) (Figure 7(aII)).
Anti-apoptotic BCL-2 mRNA expression was not detected in U-937-treated cells when
the same experimental conditions that were used for other genes and different cells were
applied (Figure 7(bI)). Anti-apoptotic BCL-XL was dose-dependently downregulated in
U-937 monocytic cells by single Dox treatments with statistical significance (p < 0.01) at
1 µM. The mRNA levels of BCL-XL were not changed in U-937 cells treated by BetA 20 µM
alone when compared to vehicle-treated cells. However, BetA 20 µM upregulated BCL-XL
expression of U-937 cells when co-treated with Dox 1 µM. This combination treatment
hindered the significant downregulating effect of Dox 1 µM and significantly increased
(p > 0.001) regulation of BCL-XL mRNA level (Figure 7(bII)).
4. Discussion
Standard chemotherapy drugs such as Dox can potently eliminate AML cells, however,
they also exert toxicity on non-transformed/non-malignant cell lines [5]. In addition, AML
is prone to cell relapse leading to production of more refractory cells that may develop
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resistance to chemotherapy and avoid apoptosis [43]. In our recent publication we reported
that Dox exhibited selectivity toward relapsed AML cells, associated with reduction of
p15-20-Bcl-2 and Beclin 1 protein expression in MOLM-13 cells [22].
Based on our preliminary studies, and reports in the literature, a concentration of
20 µM BetA was used in combination studies with clinically relevant concentrations of
Dox (0.5 and 1 µM) in the currently reported study. Reactive oxygen species generation,
pro- and anti-apoptotic Bcl-2 family and autophagy proteins, as well as gene involve-
ment in apoptotic death and autophagy modulation by BetA, Dox, and their combination
were examined.
4.1. Cytotoxic Effect of Betulinic Acid on Leukaemia Cell Lines
Anticancer effects of BetA have been studied mostly in cancers of epithelial
origin [5,7,10,44–47] with only limited studies on blood cancers. BetA has been reported to
cause a reduction of leukaemic cell viability in chronic myelogenous leukaemia (CML) cell
line, K562 [9,48] and in HL-60 (human promyelocytic leukaemia cells) [49]. In our study,
sole treatment of BetA suppressed cell viability of MOLM-13 cells (Figure 1a). However,
this effect was not seen in another AML cell line, U-937, with the same BetA concentration
(Figure 1b). Thus, BetA displayed some selectivity in MOLM-13 cells. However, it is not
clear why BetA exhibited selectivity in MOLM-13 cells—these cells are derived from a
relapsed patient.
Studies comparing human primary melanocytic (non-cancerous) and melanoma cells
showed that the normal (non-cancerous) cells were less susceptible to BetA [2]. In another
study, BetA demonstrated minimal cytotoxic effect in normal colon cells while potently
inhibiting the growth of colorectal carcinoma (HCT 116) cells in a dose-dependent man-
ner [3]. In normal blood cells, BetA tested up to a high dose of up to 110 µM on peripheral
blood lymphoblast [5] and 66 µM on peripheral blood mononuclear cells [4] did not affect
or suppress cell growth. Thus, evidence from the literature indicates that BetA potentially
targets cancerous cell lines, which is a desirable compound characteristic when treating
malignant cells.
4.2. The Effect of BetA-Dox Drug Combination on Cancer Cell Viability
BetA combinations with other forms of therapy have shown some anti-cancer po-
tential. For example, BetA showed an additive effect in combination with irradiation
therapy in melanoma cells [2]. Studies co-treating BetA with other phytochemicals such
as α-Mangostin [3] or ginsenoside Rh2 [50] showed enhanced cytotoxicity and apoptotic
death in cancer cell lines of epithelial origin. Another study combined BetA with TRAIL
(tumour necrosis factor-related apoptosis-inducing ligand) and demonstrated enhanced
apoptotic activity in various cell lines (neuroblastoma, medulloblastoma, glioblastoma and
melanoma) [51]. Therefore, in this study, BetA was selected to be tested with established
AML chemotherapy drug Dox.
Combination of BetA (20 µM) and anthracycline chemotherapy drug Dox (1 µM)
significantly reduced cell viability of MOLM-13 compared to single Dox 1 µM treatment,
the interaction between the compounds was indicative synergistic (CI < 1) in this study
(Figure 1(aII)). Fulda and Debatin (2005) [6] have hypothesised that BetA may sensitise
tumour cells to chemotherapy drugs and the authors postulated that this could be due
to combined drugs amplifying weaker death signals in apoptosis, leading to enhanced
induction of cell death. However, it must be taken into consideration that the anthracycline
class of drugs can block transcriptional induction and thus may potentially block members
of the pro-apoptotic Bcl-2 proteins stimulated by other therapies. For instance, Dox was
shown to be able to rescue cancer cell lines from cell-induced death by bortezomib and
vorinostat [52]. Therefore, it is essential to assess multiple drug effect interactions (by
combination index (CI)) of the combination therapy that utilises the anthracycline class
of drugs.
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4.3. Betulinic Acid Enhanced Anticancer Drug Activity of Doxorubicin by Sensitising the Cancer
Cell Lines to Apoptosis and ROS Formation
In this study, combination treatment of BetA and Dox hampered Dox-induced apop-
tosis in U-937 cells (Figure 2c). The selective effect of the combination treatment between
the leukaemic monocytic cells may provide some insight on targeting cells. However,
more work is required to determine how BetA differentiates and targets specific cell types.
Thus, studies on cell death mechanism of action should further proceed to determine the
difference between the molecular pathway inductions in a wider panel of cell lines.
BetA and Dox combination induced apoptotic death in the combination treatments
through an increase of late apoptotic population in MOLM-13 cells (Figure 2b), which
is more irreversible in relation to cell death [53]. A similar study by Fulda and Debatin
(2005), experimented on neuroblastoma cells and tested co-treatments of BetA (6.6, 8.8
or 10.9 µM) and Dox (0.05, 0.2 or 0.4 µM) which triggered cell death in a dose- and time-
dependent manner. The authors determined the induced cell death to be apoptotic based
on the presence of DNA fragmentation, elevation of Smac (mitochondria-derived caspase
activator), Cytochrome c release from mitochondria and activation of caspase-8, -3 and
poly-ADP-ribose polymerase (PARP) [6].
The PARP family of proteins respond to DNA damage and are involved in maintaining
genomic stability [54]. Cellular insults such as an increase in ROS formation have been
reported to activate PARP, as ROS is known to cause oxidative DNA lesions [55]. ROS
are by-products of normal cellular metabolism and in small amounts are necessary for
maintaining cellular homeostasis [56]. However, cancer cells are known to have elevated
ROS levels, which contribute to its tumorigenesis [57]. Therefore, an altered redox envi-
ronment in cancer cells makes them more sensitive to ROS/redox manipulation [56,57].
Disproportional formation of ROS in cancer cells is linked to mitochondrial membrane
deregulation; this mitochondrial damage causes several events leading to apoptosis [55].
An increase in ROS is also associated with other modes of cell death pathways [58]. We
have also previously reported that sole treatment of chronic myeloid leukaemic cell line,
K562, by the antioxidant phytochemical known as baicalein induced cell death via induc-
tion of ROS [59]. The duality of antioxidants possessing pro-oxidant properties in cancer
cells requires further studies. In the current study, single BetA had no significant effect
on ROS production in AML MOLM-13 cells (Figure 3). This is in contrast to other reports
where BetA was capable of ROS stimulation in other cancer cell lines, which the authors
linked to the compound’s ability to induce cellular death associated with mitochondrial
membrane permeabilisation [1,7–9,12,46,60–62]
Dox is a known ROS inducer. However, only supraclinical concentrations are capable
of showing this effect [63,64] which is in line with this study; only Dox 5 µM significantly
increased ROS (Figure 3). Although, BetA and low Dox concentrations alone did not alter
ROS levels in MOLM-13, the compounds together significantly elevated ROS stimulation
in MOLM-13 cell lines, showing a potential for mutual collaboration in the mechanism
of action (Figure 3). Single BetA may have not shown a direct effect on ROS generation,
but it could have sensitised the cells to enhance Dox-induced cell death through changing
ROS susceptibility in the cells. According to a study by Acésio et al. (2016) BetA and
Dox co-treatments have been shown to potentiate DNA damage, leading to an increase
in programmed cell death activation [65]. This similar effect possibly led to the rise in
apoptotic death of MOLM-13 cells, where combined drugs increased the late apoptotic cell
population, as shown in this study.
4.4. Bcl-2 Protein Family Regulation by the Combination Treatment in Apoptotic Cell Death
Overall, the differential expressions of anti-apoptotic and pro-apoptotic Bcl-2 family
of proteins in cells dictates the induction of intrinsic apoptotic pathways by regulating
permeability of the mitochondria outer membrane. A shift in their balance within the cells
can activate downstream caspases, the key effectors of apoptosis [34,66].
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From the literature, the involvement of Bcl-2 family in BetA-induced cell death is not
conclusive [7,10–12,67] and in this study, no statistical effect was noted. The regulation
of Bax protein expression was only upregulated significantly (p < 0.05) by sole treatment
of Dox and this effect was not affected by the addition of BetA to Dox (Figure 4c). Other
studies have also reported that pro-apoptotic proteins such as Bax, Bak [19,68] and Bid [69]
are upregulated and activated upon Dox treatments in certain cancer cell lines. Expressions
of mRNA, quantified as mRNA transcription, are closely associated with the protein
translation [70]. Altered expression of genes encoding for various Bcl-2 family proteins
have been documented in many human cancers including leukaemia [71]. Consistent
with the results of the protein expression in this study, when Dox was combined with
BetA, there was a significant (p < 0.05) upregulation of mRNA expression of pro-apoptotic
BAX, as well as BAK in MOLM-13 cells (Figure 6a). However, the drug combination
appeared to defend U-937 cells from Dox-induced pro-apoptotic BAX gene expression
(p < 0.001) (Figure 7a) and increased (p < 0.01) anti-apoptotic BCL-XL at the mRNA level.
The difference in the regulation between MOLM-13 and U-937 monocytic cells by the drug
combination indicates some targeting potential. This corroborates the results from the
live–dead experiments, where Dox-induced apoptotic death in U-937 cells was alleviated
with BetA combinations (Figure 2c).
Caution must be exercised to infer that ROS is involved in the modulation of apoptotic
Bcl-2 family (Bax and Bcl-2) and autophagic Beclin 1 (BH3-containing) protein expressions.
The possible synergism and enhanced cell death reported are based on cell viability and
cell death assessments, respectively. ROS activity can affect the fragile redox environment
in cancer cells and thus can distress mitochondria directly [57]. Therefore, ROS could be a
mechanism that was independent from the Bcl-2 family of protein regulation in affecting the
mitochondria. Although BetA alone did not directly affect ROS regulation, the compound
could have primed the cells to make them susceptible to ROS, thus sensitising cells to
Dox activity.
Since activated Bax migrates from the cytosolic space to mitochondrial membrane [72],
other investigative work on Bax localisation could provide a better understanding of its
activation and involvement in cell death induced by the compounds. The ratio of Bax/Bcl-2
was only weakly different between the single Dox and combination treatments. Therefore,
there may be other underlying mechanisms, not associated with Bcl-2 family regulation
that contribute to the enhanced cell death induction by the combination treatment. In
addition, understanding the role and function of the Bcl-2 isoforms specifically present in
some cancer cells may be useful for selective cell targeting leading to cell eradication as
well as modulation of several cell pathways.
4.5. Modulation of Autophagy upon Exposure by Betulinic Acid, Doxorubicin and
Drug Combination
Increases in autophagy protein markers and subsequent autophagy activation is
sometimes associated with chemotherapy treatment. The reason is not clearly defined but
it could be a cell response to drug-induced stress. Therefore, if autophagy acts as a survival
response against chemotherapy drugs, cancer cells can potentially utilise the process for
pro-survival and tumorigenic function [73]. Studies have shown that Beclin 1, an initiator
of autophagy, can be upregulated [74] or downregulated [75,76] by Dox. We report that Dox
induced cell death in MOLM-13 cells, with a decrease in the expression of Beclin 1 protein
(Figure 4d). This is in agreement with gene regulation where autophagy markers (ATG5 and
BECLIN1) were not amplified in Dox- and combination-treated MOLM-13 cells, indicating
downregulation (Figure 6c). When tested in U-937 cells, none of the drugs tested in this
study had a significant effect on Beclin 1 expression (Figure 5c). Therefore, modulatory
effects of Dox on Beclin 1 protein expression appear to be context and cell-dependent.
BetA 20 µM concentration tested in this study did not show any considerable effect
on Beclin 1 regulation in leukaemic MOLM-13 (Figure 4), nor was the protein affected by
Dox. However, a study by Yang et al. (2012) demonstrated a decrease of Beclin 1 protein
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using higher concentrations of BetA (33 µM and above), which inhibited autophagic flux
and induced apoptosis in the myeloma cell line, KM3 [77].
Beclin 1 is a BH3-containing protein that can be negatively regulated by anti-apoptotic
Bcl-2 protein and is activated by dissociating from the Beclin 1:Bcl-2 complex [33,34].
The ratio between autophagic Beclin 1 and anti-apoptotic Bcl-2 determines sensitivity to
autophagy stimuli [78,79]. Thus, an increase in the ratio denotes autophagy activation [78].
In this study, Beclin 1/Bcl-2 ratio was decreased in MOLM-13 cells by the treatments
(single Dox and combination drugs) (Figure 4(eII)), which may suggest inhibition of the
autophagy process but the drop in the ratio was more prominent with the usual p26-Bcl-2-
α and negligibly with p15-20-Bcl-2. This interplay between Bcl-2 protein family and the
autophagy effectors at mitochondrial site can regulate the machinery of both apoptosis and
autophagy, interfering with cellular metabolism and cell responses [32].
Detection of autophagic flux would give a better indication of autophagy completion,
which measures the degradation rate of the autophagy process [80]. The upregulation of
autophagic flux is represented by the enhancement of LC3 conversion (from I to II) and
decrease of p62 (reporter of ubiquitinated protein degradation) protein levels, based on the
guidelines to interpret autophagy [77,81]. Moreover, further investigations beyond marker
expressions presented in this study, and including specific markers are required to assess
the nature of this potential autophagy modulation.
5. Conclusions
The combination treatment of BetA and Dox showed indicative synergistic cytotoxic ef-
fect on AML MOLM-13 cell lines. BetA in the drug combination did not affect Dox-induced
death regulation by Bcl-2 family and Beclin 1. However, increases in ROS generation by the
combination treatment could be a mechanical factor that enhanced cell death, resulting in
drug synergism in MOLM-13 cells, which led to an increase in more cells undergoing late
apoptosis. On the contrary, this combination treatment hindered the Dox apoptotic effect
in AML cell line U-937 by salvaging cell viability, which was associated with the mRNA
regulation of Bcl-2 family. Thus, the effect of the compounds together induced cell death as
well as cell-dependent protective effects.
Studies are currently underway, and they include work with specific inhibitors target-
ing apoptosis and autophagy to determine the interplay between the two processes in cell
death induction. Future work will also include knock-in and knock-out experiments on
MOLM-13, U-937, and other cells to verify the role of the p15-20 protein in drug-treated
cells. The localisation of marker proteins within cells will also be studied. Additionally,
work is required to verify if the enhanced ROS generation, observed by the drug combi-
nation, could have contributed to the synergistic effect that augmented apoptotic activity
through direct mitochondrial membrane disruption.
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